Exploring the Relationship between the Inhibition Selectivity and the Apoptosis of Roscovitine-Treated Cancer Cells

被引：3

作者：

Cui, Chunying ^{[1
]}

Wang, Yaonan ^{[2
]}

Wang, Yuji ^{[1
]}

Zhao, Ming ^{[1
]}

Peng, Shiqi ^{[1
]}

机构：

[1] Capital Med Univ, Coll Pharmaceut Sci, Beijing 100069, Peoples R China

[2] Capital Med Univ, Med Expt & Test Ctr, Beijing 100069, Peoples R China

来源：

JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY | 2013年 / 2013卷

关键词：

DEPENDENT KINASE INHIBITOR; R-ROSCOVITINE; CDK INHIBITOR; IN-VITRO; CYC202; POTENT;

D O I：

10.1155/2013/389390

中图分类号：

O65 [分析化学];

学科分类号：

070302 [分析化学];

摘要：

The antitumor activity of roscovitine was tested in four cervical carcinoma cells: C33A, HCE-1, HeLa, and SiHa. The effects of roscovitine on ATP Lite assay, cell cycle, and apoptosis were assessed. The Sub-G(1) DNA content occurred great increasing, and this indicates that apoptosis was induced quickly in HeLa cells, but slowly in the other cells. The morphological observation results showed that roscovitine induced apoptosis and cell death in the cervical carcinoma cells. Results revealed that roscovitine exhibited selective cytotoxicity towards 4 cervical carcinoma cells, and the cells showed different morphologic and apoptotic changes at the same concentration. It was estimated that cervical carcinoma cells responded differently to roscovitine because of differences in apoptotic and genetic background in different cervical carcinoma cells. This study suggested that roscovitine had the potential to be a chemotherapeutic agent against cervical carcinoma.

引用

页数：7

共 14 条

[1]

Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells [J].

David-Pfeuty, T .

ONCOGENE, 1999, 18 (52) :7409-7422

[2]

Gallorini M, 2012, BIODRUGS, V26, P377, DOI 10.2165/11634060-000000000-00000

[3]

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies [J].

Le Tourneau, Christophe ;

Faivre, Sandrine ;

Laurence, Valerie ;

Delbaldo, Catherine ;

Vera, Karina ;

Girre, Veronique ;

Chiao, Judy ;

Armour, Sian ;

Frame, Sheelagh ;

Green, Simon R. ;

Gianella-Borradori, Athos ;

Dieras, Veronique ;

Raymond, Eric .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (18) :3243-3250

[4]

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) [J].

McClue, SJ ;

Blake, D ;

Clarke, R ;

Cowan, A ;

Cummings, L ;

Fischer, PM ;

MacKenzie, M ;

Melville, J ;

Stewart, K ;

Wang, SD ;

Zhelev, N ;

Zheleva, D ;

Lane, DP .

INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (05) :463-468

[5]

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 [J].

Meijer, L ;

Borgne, A ;

Mulner, O ;

Chong, JPJ ;

Blow, JJ ;

Inagaki, N ;

Inagaki, M ;

Delcros, JG ;

Moulinoux, JP .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :527-536

[6]

Mgbonyebi OP, 1999, CANCER RES, V59, P1903

[7]

Mihara M, 2002, INT J ONCOL, V21, P95

[8]

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma [J].

Raje, N ;

Kumar, S ;

Hideshima, T ;

Roccaro, A ;

Ishitsuka, K ;

Yasui, H ;

Shiraishi, N ;

Chauhan, D ;

Munshi, NC ;

Green, SR ;

Anderson, KC .

BLOOD, 2005, 106 (03) :1042-1047

[9]

Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo [J].

Tirado, OM ;

Mateo-Lozano, S ;

Notario, V .

CANCER RESEARCH, 2005, 65 (20) :9320-9327

[10]

INHIBITION OF CYCLIN-DEPENDENT KINASES BY PURINE ANALOGS [J].

VESELY, J ;

HAVLICEK, L ;

STRNAD, M ;

BLOW, JJ ;

DONELLADEANA, A ;

PINNA, L ;

LETHAM, DS ;

KATO, J ;

DETIVAUD, L ;

LECLERC, S ;

MEIJER, L .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 224 (02) :771-786

← 1 2 →